Related Experiment Video
Updated: Aug 12, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
[Different sensitivity of two chronic myeloid leukemia cell lines to interferon-alpha]
Xin-Mei Li1, Han-Chun Chen, Xin-Fa Liu
1Molecular Biology Research Center, Xiangya Medical College, Central South University, Changsha, Hunan, 410078, PR China.
Insights
Interferon-alpha (IFN-alpha) effectively treats some chronic myeloid leukemia (CML) patients, but not all. This study reveals that different CML cell lines exhibit varying sensitivity to IFN-alpha, impacting treatment outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Context:
- Interferon-alpha (IFN-alpha) is a key therapeutic for hematologic malignancies and lymphoma.
- While effective for many, IFN-alpha only induces remission in 70-80% of chronic myeloid leukemia (CML) patients.
- The underlying mechanisms for differential CML response to IFN-alpha remain unclear.
Purpose:
- To investigate the differential sensitivity of CML cell lines to IFN-alpha.
- To analyze the effects of IFN-alpha on CML cell growth, apoptosis, and bcr/abl gene expression.
- To elucidate the molecular basis for variable patient responses to IFN-alpha therapy.
Summary:
- KT-1/A3 CML cells showed dose-dependent growth inhibition and increased apoptosis with IFN-alpha, accompanied by a significant decrease in bcr/abl gene expression.
- K562 CML cells demonstrated no significant changes in growth, apoptosis, or bcr/abl expression when treated with IFN-alpha.
- These findings indicate distinct cellular responses to IFN-alpha between different CML cell populations.
Impact:
- Highlights the heterogeneity of CML cell populations in their response to IFN-alpha.
- Provides insights into potential mechanisms driving differential therapeutic efficacy in CML.
- Suggests the need for personalized treatment strategies based on CML cell characteristics.
Background & Objective:
The clinical observation has shown that interferon-alpha(IFN-alpha) is one of the most effective therapeutic agents for the malignancies of hemopoietic system and lymphoma. However, IFN-alpha can only induce about 70-80% of the patients with chronic myeloid leukemia (CML) to get hematological remission. The mechanism by which various CML cases respond differently to IFN-alpha is still unclear.
Methods:
(1)The effects of IFN-alpha in different concentrations (100, 500, 1,000, 5,000, and 10,000 U/ml) on growth of the two CML cell lines were detected by MTT assay,semisolid colony formation and trypan-blue staining for the cells in liquid culture. (2)The cell apoptosis was examined by flow cytometry(FCM),fluorescence microscopy and gel electrophoresis analysis for DNA fragmentation in 48 hours after IFN-alpha (1,000 U/ml) induction of both KT-1/A3 and K562 cells. (3)The expression levels of bcr/abl chimeric genes were analyzed by relative quantitative RT-PCR at 48 hours after cultivation of both KT-1/A3 and K562 cells with IFN-alpha in 1,000 U/ml.
Results:
(1)The growth inhibition of KT-1/A3 cells was dose-dependent in IFN-alpha from the concentration of 100 U/ml to 10,000 U/ml. (2)Having been induced with IFN-alpha in 1000 U/ml for 48 hours, the apoptosis rate of KT-1/A3 cells raised from 3.29% to 11.8% and the expression level of bcr/abl chimeric gene in this cell line declined to 66.7% as compared with those of the control. (3)The growth and apoptosis rate as well as bcr/abl gene expression level of K562 cells were not significantly affected by IFN-alpha.
Conclusion:
Different populations of CML cells shows different sensitivity to IFN-alpha.
